Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christos Kiamouris"'
Autor:
Christos Alamanis, Christos Kiamouris, Charalambos Deliveliotis, Michael Koutsilieris, Anastasios Zervas, Meletios A. Dimopoulos, Aris Giannopoulos, Dimitra Gika, Constantinos Constantinidis
Publikováno v:
Urology. 63:120-125
Objectives To evaluate prospectively the combination of a luteinizing hormone-releasing hormone analog with a somatostatin analog and dexamethasone in patients with hormone-refractory prostate cancer (HRPC) in a randomized Phase II study. HRPC presen
Autor:
Haralambos P. Kalofonos, Christos Kiamouris, Gerasimos Aravantinos, Athanasios M. Dimopoulos, Oneynadum Adimchi, G. Fountzilas, Adamos Adamou, Dimosthenis Skarlos, Georgios Fotios Samelis, Paris Kosmides
Publikováno v:
Urology. 61:1211-1215
Objectives To consider the safety profile and therapeutic value of the combination of estramustine and mitoxantrone in a bimonthly schedule to treat hormone-refractory prostate cancer. The survival of patients with prostate cancer who relapse after a
Autor:
Christos Kiamouris, Christos Karkantaris, Nora Viniou, Chrisanthi Mitsouli, Constantinos Zervas, A. Zomas, Dimitra Gika, Vassiliki Grigoraki, John Christakis, Meletios A. Dimopoulos, Nikolaos Anagnostopoulos
Publikováno v:
Journal of Clinical Oncology. 20:2327-2333
PURPOSE: Waldenström’s macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma in which CD20 is usually expressed on tumor cells. There is evidence that patients with WM may benefit from treatment with the anti-CD20 monoclonal antibody ri
Autor:
Stylianos Michalas, Christos A. Papadimitriou, Christos Kiamouris, Alexandros Rodolakis, Meletios A. Dimopoulos, Charalambos Kouroussis, Dimitra Gika, Emmanuel Diakomanolis, Lia A. Moulopoulos, Georgios Vlahos
Publikováno v:
Cancer. 92:1856-1863
BACKGROUND The combination of paclitaxel with a platinum analogue is the preferred chemotherapy regimen in the treatment of advanced epithelial ovarian carcinoma. The alkylating agent ifosfamide has shown activity in refractory or recurrent ovarian c
Publikováno v:
Hematology/Oncology Clinics of North America. 13:1249-1257
A small proportion of patients with plasma cell myeloma have a solitary plasmacytoma of bone. Strict staging criteria, including normal MR imaging studies of the axial skeleton and the long bones and absence of monoclonal plasma cells detected by flo
Autor:
Ersi, Voskaridou, Athanasios, Anagnostopoulos, Kostas, Konstantopoulos, Eleni, Stoupa, Evgenia, Spyropoulou, Christos, Kiamouris, Evangelos, Terpos
Publikováno v:
Haematologica. 91(9)
The aim of this study was to evaluate the effect of zoledronic acid (ZA) on thalassemia-induced osteoporosis.We studied 66 thalassemia patients with osteoporosis, who were randomized to receive 4 mg ZA iv, every 6 months (23 patients; group A) or eve
Autor:
Georgios Fotios Samelis, Haralambos Kalofonos, Adamos Adamou, Paris Kosmides, Dimosthenis Skarlos, Gerasimos Aravantinos, Christos Kiamouris, Oneynadum Adimchi, Georgios Fountzilas, Athanasios Meletios Dimopoulos
Publikováno v:
Urology. 66(2)
To evaluate the safety profile and therapeutic value of the combination of estramustine, mitoxantrone, and vinorelbine in the treatment of hormone-refractory prostate cancer.Fifty-two patients with hormone-refractory prostate cancer were included in
Autor:
Ae, Roussidis, Tn, Mitropoulou, Ad, Theocharis, Christos Kiamouris, Papadopoulos S, Kletsas D, Nk, Karamanos
Publikováno v:
Europe PubMed Central
STI571, a specific tyrosine kinase inhibitor, exhibits a substantial therapeutic activity in patients with chronic myeloid leukaemia and gastrointestinal stromal tumors. In this study we examined the activity of STI571 on the growth and invasiveness
Autor:
A. Anagnostopoulos, George Fountzilas, Meletios A. Dimopoulos, George Mantzios, C. Nicolaides, Efstathios Papageorgiou, Theofanis Economopoulos, Christos Kiamouris
Publikováno v:
Leukemialymphoma. 43(1)
The treatment of patients with recurrent low-grade lymphoma with the combination of fludarabine, mitoxantrone and dexamethasone has been associated with significant activity but has also caused frequent infectious complications. We designed a phase I
Autor:
N. Xiros, D.G. Pectasides, Dimitris Bafaloukos, C. Nicolaides, Meletios A. Dimopoulos, H. P. Kalofonos, Christos Kiamouris, A. Visvikis, Gerassimos Aravantinos
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(10)
Summary Purpose The aim of the study was to evaluate the efficacy and safety of the combination of gemcitabine and ifosfamide as a second-line treatment for advanced urothelial cancer. Patients and methods Thirty-four patients with metastatic urothel